Unknown

Dataset Information

0

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.


ABSTRACT: Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.

SUBMITTER: Abonour R 

PROVIDER: S-EPMC8048460 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9176048 | biostudies-literature
| S-EPMC6899784 | biostudies-literature
| S-EPMC6039656 | biostudies-literature
| S-EPMC6943143 | biostudies-literature
| S-EPMC6208675 | biostudies-literature
| S-EPMC5132115 | biostudies-literature
| S-EPMC9776506 | biostudies-literature
| S-EPMC7540439 | biostudies-literature
| S-EPMC10264885 | biostudies-literature